课题基金 / 基金详情

Cell Therapy Core: GMP/Vector Labs

Cell Therapy Core: GMP/Vector Labs
细胞治疗核心:GMP/Vector Labs
批准号:
10247035
负责人:
Indreshpal Kaur
金额:
$40.42万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-22 至 2023-08-31
关键词:
AccreditationAir MovementsAntigensBK VirusBar CodesBasic ScienceBlood CellsBlood Component RemovalBone MarrowCASP9 geneCD19 geneCancer CenterCell TherapyCellsChemistryChildChildhoodClinicalClinical ResearchClinical TrialsCodeCytomegalovirusCytotoxic T-LymphocytesDendritic CellsDisadvantagedDiseaseDocumentationDoseEngraftmentEnhancement TechnologyEnsureEnvironmental MonitoringFoundationsFreezingGene-ModifiedGenetic EngineeringGoalsGrantGuanosine TriphosphateHIVHealth systemHematopoieticHematopoietic stem cellsHuman Herpesvirus 4Human ResourcesImmunotherapyIncubatorsIndustryInfrastructureInstitutionInterleukin-15Investigational DrugsInvestigational New Drug ApplicationK562 CellsLaboratoriesLaboratory StudyMaintenanceMalignant NeoplasmsMalignant lymphoid neoplasmMedical centerMonitorMyelogenousNatural Killer CellsPatientsPediatric HospitalsPhasePhysiologic pulsePreparationProcessProductionProgram Research Project GrantsQuality ControlRefractoryRegulationRegulatory T-LymphocyteResearch PersonnelResource SharingServicesSourceStructureSystemT-LymphocyteTemperatureTestingTherapeuticTissuesTranslationsTransplantationTumor-Infiltrating LymphocytesUmbilical Cord BloodUmbilical Cord Blood TransplantationViruschemotherapychimeric antigen receptorclinical implementationengineered T cellsexperiencegene therapygenetically modified cellsgraft vs host diseasehigh riskimmune reconstitutionlymphoblastoid cell linemanufacturing facilitymesenchymal stromal cellnanoparticlenovelnovel therapeuticsoperationperipheral bloodpreclinical studypressureprogenitorprogramsquality assurancestemstem cellssuicide genetumorvector

项目摘要

项目成果

Indreshpal Kaur的其他基金

相关文献

中文摘要
翻译
项目总结 该计划项目赠款(PO1)探索通过以下方式促进脐带血移植(CBT) 利用体外扩增脐血干/祖细胞、自然杀伤(NK)细胞和T细胞 在临床前研究和临床试验中表达嵌合抗原受体(CARS)和病毒特异性T细胞。全 在研究过程中,四个项目将进行临床试验。这取决于是否有可用的 GMP生产设施,用于细胞治疗产品的制备。项目1、3和4将在 MD Anderson癌症中心(MDACC)和项目2的GMP设施将 依靠国家儿童医学中心(CNHS)的GMP设施-细胞增强和技术 用于免疫治疗(CETI)。MDACC的GMP设施已经运行了15年以上, CNHS-CETI的GMP是一家新设施,于2013年开业。这两个机构的细胞处理设施 在制备各种蜂窝产品方面拥有相当丰富的经验,两人都获得了更多- 来自细胞治疗认可基金会(FACT)的最低限度的细胞治疗认证。 这两个设施都有良好的设备,可以在GMP条件下运行,拥有广泛的文件系统, 条形码、环境监测以及质量保证、控制和改进计划。一个 在两个设施中都提供了独立和经过验证的警报系统,以监测、记录和报警温度 所有保温箱、冰箱和冷冻室中的空气;每个生物安全柜中的气流;以及差压 ISO 7和ISO 8实验室之间的大门。核心的其他组件是质量 CNHS-CETI和MDACC的控制实验室,对蜂窝产品进行内部测试,并 负责GMP实验室和质量保证小组的日常监督,以确保合规性 符合cGMP法规,并提供制造和放行的所有方面的独立概述。这个 这两家机构的GMP人员都有丰富的监管经验,这将促进 临床试验的实验室研究。在这项计划中,MDACC将生产五种细胞治疗产品。 项目1:扩大的CB细胞,已经岩藻糖化以增强植入,以及岩藻糖化 间充质基质细胞(MSCs)用于治疗移植物抗宿主病。项目3:CB NK细胞遗传 修饰表达针对CD19+淋巴瘤的嵌合抗原受体(CAR),表达IL-1 15,以及一个可诱导的caspase 9自杀基因。对于项目4:表达靶向Pr1+的Car的CB T细胞 骨髓性癌症。项目2:CNHS-CETI将生产针对CMV的CB多病毒特异性T细胞, EBV、腺病毒和BK病毒,以及将用于患者的新型HIV特异性T细胞产品 患有艾滋病毒的人..总之,GMP实验室核心是P01的重要组成部分,它将提供 为实施项目1、2、3和4中的临床研究提供基本服务。
英文摘要
PROJECT SUMMARY This Program Project Grant (PO1) explores the enhancement of cord blood transplantation (CBT) by employing ex-vivo expansion of CB stem/progenitors, natural killer (NK) cells and T cells engineered to express chimeric antigen receptors (CARs), and virus-specific T cells in preclinical studies and clinical trials. All four projects will undertake clinical trials during the course of the studies. These rely on the availability of a GMP manufacturing facility for the preparation of the cellular therapy products. Projects 1, 3 and 4 will use on the Good Manufacturing Practice (GMP) Facility at MD Anderson Cancer Center (MDACC) and Project 2 will rely on the GMP Facility at Children's National Medical Center (CNHS)-Cell Enhancement and Technologies for Immunotherapy (CETI). The GMP Facility at MDACC has been in operation for more than 15 years and the GMP at CNHS-CETI is a new facility, which opened in 2013. The Cell Processing Facilities at both institutions have considerable experience in the preparation of a wide variety of cellular products and both received more- than-minimal cell therapy accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT). Both Facilities are well equipped to operate under GMP conditions, with extensive documentation systems, barcoding, environmental monitoring, and quality assurance, control and improvement programs. An independent and validated alarm system is provided in both facilities to monitor, log and alarm the temperature in all incubators, refrigerators and freezers; the airflow in each biosafety cabinet; and differential pressure across doors between the ISO 7 and ISO 8 laboratories. Additional components of the Core are the Quality Control Laboratories at CNHS-CETI and MDACC, which perform in-house testing of cellular products, and are responsible for routine monitoring of the GMP Laboratory and Quality Assurance Group to ensure compliance with cGMP regulations and provides independent overview of all aspects of manufacturing and release. The GMP personnel at both institutions have extensive regulatory experience that will facilitate the translational of laboratory studies into clinical trials. In this proposal, MDACC will manufacture five cellular therapy products. For Project 1: expanded CB cells that have been fucosylated to enhance engraftment, and fucosylated mesenchymal stromal cells (MSCs) to treat graft versus host disease. For Project 3: CB NK cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19+ lymphoid cancers which expresses IL- 15, and an inducible caspase 9 suicide gene. For Project 4: CB T cells expressing a CAR targeting Pr1+ myeloid cancers. For Project 2: CNHS-CETI will manufacture CB multi-virus-specific T cells targeting CMV, EBV, adenovirs and BK virus, as well as the novel HIV-specific T cell product which will be used for patients with HIV disease.. In summary, the GMP Laboratory Core is a vital component of the P01 that will provide essential services to the implementation of the clinical studies in Projects 1, 2, 3 and 4.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell Therapy Core: GMP/Vector Labs
Cell Therapy Core: GMP/Vector Labs